All In Biotech

NDA 008975 · Ani Pharms

Purified Cortrophin Gel

Corticotropin · Injection · Adrenocorticotropic Hormone

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1954

Jun 16, 1954

Approved uses

1

Original approval plus efficacy supplements

Registered trials

176

26 Phase 3, 13 recruiting

FAERS reports

12

9 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

INDICATIONS AND USAGE Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 16, 1954 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • PURIFIED CORTROPHIN GEL · CORTICOTROPIN 40 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • PURIFIED CORTROPHIN GEL · CORTICOTROPIN 80 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Corticotropin" as an intervention, any sponsor and status, largest first.

All 176 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain3
  • dizziness2
  • fatigue2
  • peripheral swelling2
  • anxiety1
  • arthralgia1
  • back pain1
  • blood glucose increased1
  • blood potassium increased1
  • blood pressure decreased1
  • blood pressure increased1
  • blood uric acid decreased1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20242
20255
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 591 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.